Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Patients' Perceptions of Nusinersen Effects According to Their Responder Status

C. Lilien, E. Vrscaj, G. Thapaliya, N. Deconinck, L. De Waele, T. Duong, J. Haberlová, M. Kumhera, G. Peirens, L. Szabo, V. Tahon, WJ. Tang, N. Benmhammed, L. Médard, L. Servais

. 2024 ; 13 (12) : . [pub] 20240611

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012555

Background and Objective: Patients with spinal muscular atrophy (SMA) treated with a disease-modifying therapy (DMT) are often classified as responders or non-responders based on the attainment of a specific improvement threshold on validated functional scales. This categorization may significantly impact treatment reimbursement in some countries. The aim of this research is to evaluate the perception of treatments and their benefit by patients considered as responders or non-responders. Methods: In this non-commercial multicenter study, 99 post-symptomatically treated SMA type I-III patients with a median age of 11.2 (0.39-57.4) years at treatment initiation were stratified into three groups based on their treatment outcomes, i.e., those exhibiting clinically significant improvement (N = 41), those with non-clinically significant improvement (N = 18), or those showing no improvement (N = 40). Fifteen months after treatment, the initiation patients or patients' caregivers were assessed using a patient-rated scoring system based on the Patient Global Impression of Change (PGIC) scale, comprising 22 questions targeting important aspects and tasks in the daily life of patients with SMA. Results: We found no statistical difference in the patient perception of treatment benefits in 17 out of 22 domains across patient groups. Conclusions: Our results suggest that functional motor scales do not recapitulate patients' and patients' caregivers' experience of the effect of nusinersen treatment in SMA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012555
003      
CZ-PrNML
005      
20240726151401.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm13123418 $2 doi
035    __
$a (PubMed)38929947
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Lilien, Charlotte $u MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK $1 https://orcid.org/0009000182196996
245    10
$a Patients' Perceptions of Nusinersen Effects According to Their Responder Status / $c C. Lilien, E. Vrscaj, G. Thapaliya, N. Deconinck, L. De Waele, T. Duong, J. Haberlová, M. Kumhera, G. Peirens, L. Szabo, V. Tahon, WJ. Tang, N. Benmhammed, L. Médard, L. Servais
520    9_
$a Background and Objective: Patients with spinal muscular atrophy (SMA) treated with a disease-modifying therapy (DMT) are often classified as responders or non-responders based on the attainment of a specific improvement threshold on validated functional scales. This categorization may significantly impact treatment reimbursement in some countries. The aim of this research is to evaluate the perception of treatments and their benefit by patients considered as responders or non-responders. Methods: In this non-commercial multicenter study, 99 post-symptomatically treated SMA type I-III patients with a median age of 11.2 (0.39-57.4) years at treatment initiation were stratified into three groups based on their treatment outcomes, i.e., those exhibiting clinically significant improvement (N = 41), those with non-clinically significant improvement (N = 18), or those showing no improvement (N = 40). Fifteen months after treatment, the initiation patients or patients' caregivers were assessed using a patient-rated scoring system based on the Patient Global Impression of Change (PGIC) scale, comprising 22 questions targeting important aspects and tasks in the daily life of patients with SMA. Results: We found no statistical difference in the patient perception of treatment benefits in 17 out of 22 domains across patient groups. Conclusions: Our results suggest that functional motor scales do not recapitulate patients' and patients' caregivers' experience of the effect of nusinersen treatment in SMA.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vrscaj, Eva $u Division of Child Neurology, Reference Center for Neuromuscular Diseases, Department of Paediatrics, University Hospital Liege & University of Liege, 4000 Liege, Belgium $u Department for Pediatric Neurology, University Children's Hospital, University Medical Centre Ljubljana, Bohoričeva 20, 1525 Ljubljana, Slovenia $1 https://orcid.org/0000000215100501
700    1_
$a Thapaliya, Gita $u MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK
700    1_
$a Deconinck, Nicolas $u NMRC UZ Gent, Ghent University Hospital, 9000 Ghent, Belgium $u Neuromuscular Reference Center and Department of Paediatric Neurology, Hôpital Universitaire des Enfants Reine Fabiola, HUB, Université Libre de Bruxelles, 1020 Brussels, Belgium
700    1_
$a De Waele, Liesbeth $u Department of Paediatrics, University Hospitals Leuven, 3000 Leuven, Belgium $u Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
700    1_
$a Duong, Tina $u John W. Day Lab, Department of Neurology and Neurological Sciences, University of Stanford, Stanford, CA 94305, USA
700    1_
$a Haberlová, Jana $u Department of Paediatric Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Praha, Czech Republic
700    1_
$a Kumhera, Markéta $u Department of Paediatric Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Praha, Czech Republic $1 https://orcid.org/0000000349674797
700    1_
$a Peirens, Geertrui $u Department of Paediatrics, University Hospitals Leuven, 3000 Leuven, Belgium
700    1_
$a Szabo, Lena $u Paediatric Center, Semmelweis University, 1083 Budapest, Hungary
700    1_
$a Tahon, Valentine $u NMRC UZ Gent, Ghent University Hospital, 9000 Ghent, Belgium
700    1_
$a Tang, Whitney J $u John W. Day Lab, Department of Neurology and Neurological Sciences, University of Stanford, Stanford, CA 94305, USA
700    1_
$a Benmhammed, Noor $u Division of Child Neurology, Reference Center for Neuromuscular Diseases, Department of Paediatrics, University Hospital Liege & University of Liege, 4000 Liege, Belgium
700    1_
$a Médard, Laurie $u Division of Child Neurology, Reference Center for Neuromuscular Diseases, Department of Paediatrics, University Hospital Liege & University of Liege, 4000 Liege, Belgium
700    1_
$a Servais, Laurent $u MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK $u Division of Child Neurology, Reference Center for Neuromuscular Diseases, Department of Paediatrics, University Hospital Liege & University of Liege, 4000 Liege, Belgium $1 https://orcid.org/0000000192704061
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 13, č. 12 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38929947 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151354 $b ABA008
999    __
$a ok $b bmc $g 2125406 $s 1224418
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 13 $c 12 $e 20240611 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace